MedTrace Logo

Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer

NCT02256852 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-02-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.

Conditions

Interventions

BIOLOGICAL

QBKPN SSI

QBKPN SSI is administered subcutaneously for 12 weeks

Sponsors & Collaborators

  • Qu Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Dr. Stephen Lam · British Columbia Cancer Agency

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02256852 on ClinicalTrials.gov